New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
10:00 EDTANDE, VNCE, TWTR, PTRY, LGCY, FORM, DWA, COP, AUXL, AZO, WSMOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Andersons (ANDE) upgraded at BMO Capital... AutoZone (AZO) upgraded to Buy from Hold at Gabelli... Auxilium (AUXL) upgraded at MKM Partner... ConocoPhillips (COP) upgraded to Buy from Neutral at Guggenheim... DreamWorks Animation (DWA) upgraded to Hold from Sell at Topeka... FormFactor (FORM) upgraded at B. Riley... Legacy Reserves (LGCY) upgraded to Top Pick from Outperform at RBC Capital... The Pantry (PTRY) upgraded to Outperform from Neutral at Macquarie... Twitter (TWTR) upgraded at Nomura... Vince Holding (VNCE) upgraded to Buy from Hold at KeyBanc... Williams-Sonoma (WSM) upgraded to Overweight from Neutral at Piper Jaffray.
News For ANDE;AZO;AUXL;COP;DWA;FORM;LGCY;PTRY;TWTR;VNCE;WSM From The Last 14 Days
Check below for free stories on ANDE;AZO;AUXL;COP;DWA;FORM;LGCY;PTRY;TWTR;VNCE;WSM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 12, 2014
12:26 EDTTWTRTwitter introducing promoted video beta for advertisers
Subscribe for More Information
12:04 EDTTWTRStocks with call strike movement; PBR TWTR
Subscribe for More Information
08:03 EDTWSMGoldman's Retail selections for Q2
Goldman is most above Q2 consensus for Advance Auto Parts (AAP), Best Buy (BBY) and Williams-Sonoma (WSM), sees best risk/reward in Ulta Salon (ULTA) and Sportsman's Warehouse (SPWH), and low visibility in Dick's Sporting (DKS) and Wal-Mart (WMT).
06:03 EDTTWTRTwitter says paid $134.1M for Gnip
In May, the company completed its acquisition of privately held Gnip, a provider of social data and analytics headquartered in Boulder, Colorado. The acquisition is expected to allow the Company to further enhance its data analytics capabilities. Under the terms of the acquisition, the company agreed to pay $107.3M in cash and issue a total of 0.6M shares of common stock including shares of restricted stock subject to continued employment in consideration of all of the issued and outstanding shares of capital stock of Gnip. In addition, the Company agreed to issue up to 0.4M shares of the company’s stock as a result of assumed Gnip equity awards held by individuals, who will continue to provide services to the Company. The fair value of total consideration of $134.1M. During the six months ended June 30, the company acquired four other companies, which were accounted for as business combinations. The total purchase price of $55.5M for these acquisitions was preliminarily allocated as follows: $9.2M to developed technologies, $1.4M to net tangible assets acquired based on their estimated fair value on the acquisition date, $1.3M to deferred tax liability, and the excess $46.2M of the purchase price over the fair value of net assets acquired to goodwill. Goodwill resulting from these acquisitions is not expected to be deductible for U.S. income tax purposes.
06:00 EDTTWTRTwitter believes approx. 11% of active users only using third-party apps
Subscribe for More Information
August 11, 2014
16:00 EDTTWTROptions Update; August 11, 2014
iPath S&P 500 VIX Short-Term Futures down 1.33 to 31.90. Option volume leaders: AAPL KMI MNKD PBR AMZN SCTY TWTR TSLA according to Track Data.
13:40 EDTTWTRTwitter sees strong demand in China, hopes to enter market, Nikkei says
Subscribe for More Information
11:04 EDTAUXLActive equity options trading on open
Subscribe for More Information
09:36 EDTTWTRActive equity options trading on open
Subscribe for More Information
06:09 EDTAUXLAuxilium appoints Andrew Saik as CFO
Subscribe for More Information
August 8, 2014
16:00 EDTTWTROptions Update; August 8, 2014
Subscribe for More Information
12:01 EDTTWTRTwitter revamps its advertising fees to attract more businesses
Subscribe for More Information
10:00 EDTANDEOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Activision Blizzard (ATVI) upgraded to Buy from Neutral at Longbow... Allergan (AGN) upgraded to Outperform from Market Perform at Leerink... Andersons (ANDE) upgraded to Buy from Hold at Feltl... Arista Networks (ANET) upgraded to Buy from Neutral at Citigroup... Barrick Gold (ABX) upgraded to Conviction Buy from Buy at Goldman... Brinker (EAT) upgraded to Outperform from Market Perform at Raymond James... CF Industries (CF) upgraded to Buy from Hold at Feltl... CST Brands (CST) upgraded to Neutral from Underperform at Credit Suisse... Cimarex Energy (XEC) upgraded to Accumulate from Hold at KLR Group... Coca-Cola HBC (OCCH) upgraded to Buy from Hold at Deutsche Bank... Delek US (DK) upgraded to Outperform at Cowen... Fifth Street Finance (FSC) upgraded to Buy from Neutral at Guggenheim... Glimcher Realty Trust (GRT) upgraded to Buy from Neutral at BofA/Merrill... Goodrich Petroleum (GDP) upgraded to Strong Buy from Outperform at Raymond James... Monster Beverage (MNST) upgraded to Neutral from Underperform at Longbow... NIC Inc. (EGOV) upgraded to Outperform from Market Perform at Barrington... NVIDIA (NVDA) upgraded at Needham... POZEN (POZN) upgraded to Buy from Hold at Ascendiant... Power Solutions (PSIX) upgraded to Accumulate from Neutral at Global Hunter... Primoris (PRIM) upgraded to Buy from Hold at BB&T... Sierra Bancorp (BSRR) upgraded to Outperform from Market Perform at Raymond James... Sonus Networks (SONS) upgraded to Outperform from Market Perform at Barrington... Stone Energy (SGY) upgraded to Buy from Accumulate at KLR Group... Tornier (TRNX) upgraded at BMO Capital... Tyson Foods (TSN) upgraded to Buy from Hold at BB&T... WGL Holdings (WGL) upgraded to Buy from Hold at Brean Capital.
09:27 EDTANDEAndersons upgraded to Buy from Hold at Feltl
Subscribe for More Information
08:34 EDTAUXLBioSpecifics announces initiation of Phase 2 clinical study of CCH
BioSpecifics (BSTC) announced that it has injected the first patient in its placebo-controlled Phase 2 clinical trial of CCH for the treatment of lipoma. The company expects to complete patient enrollment in this trial during the first quarter of 2015. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study to assess the safety and efficacy of CCH for the treatment of lipoma. The primary endpoint of the Phase 2 clinical trial is the reduction in the measureable surface area of the target lipomas, as determined by caliper, at six months post injection. The secondary efficacy endpoints include responders at six months post injection who show a ≥50% decrease in lipoma surface area relative to baseline between CCH and placebo, the change in the length of the target lipoma, the relative change in lipoma surface area as measured by caliper at one month and three months, and the relative change in lipoma volume as measured by MRI. The study will also gather qualitative lipoma characteristics and an assessment of patient satisfaction through a questionnaire administered to each subject prior to injection and at each follow-up visit. BioSpecifics' strategic partner Auxilium (AUXL) has the option to license development and marketing rights to this indication based on a full analysis of the data from this Phase 2 clinical trial, which would transfer responsibility for the future development costs to Auxilium and trigger an opt-in payment and potential future milestone and royalty payments from Auxilium to BioSpecifics.
08:11 EDTANDEAndersons price target raised to $65 from $56 at BMO Capital
Subscribe for More Information
August 7, 2014
10:20 EDTAUXLHigh option volume stocks
Subscribe for More Information
08:36 EDTCOPConocoPhillips weakness creates favorable entry point, says Argus
Subscribe for More Information
06:17 EDTAUXLAuxilium backs FY14 revenue guidance of $380M-$420M, consensus $397.45M
Subscribe for More Information
06:16 EDTAUXLAuxilium reports Q2 EPS (44c), consensus (21c)
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use